AbbVie Inc. Stock

AbbVie Inc. (ABBV) — FY2025 Annual Report

AbbVie closed FY2025 with record revenue of roughly $61.2 billion, up about 9% year-over-year, yet net income attributable to the company edged slightly lower to $4.23 billion. The combination of top-line acceleration and stagnant bottom-line results appears to define the year, alongside a notable balance sheet development: total stockholders' equity turned negative, sliding to a deficit of approximately $3.3 billion from a positive $3.3 billion the year prior.

The revenue growth seems to reflect momentum in the immunology franchise, though profitability tells a more nuanced story. Operating earnings rebounded meaningfully to about $15.1 billion, and operating margin recovered to roughly 25% from the compressed 16% of FY2024, which may indicate the prior year was weighed down by elevated one-time charges. What stands out most, however, is the surge in acquired IPR&D and milestone expenses, which climbed to roughly $5 billion from $2.8 billion, and the continued heavy amortization of intangibles near $7.4 billion. These items appear to be the primary reason net margin remains around 7% despite gross margins holding steady above 70%. When compared to the 20%+ net margins of FY2021–2022, the current profitability profile could suggest the business is still absorbing the earnings drag from its post-Humira transition and aggressive acquisition activity.